Attached files
file | filename |
---|---|
EX-99 - VistaGen Therapeutics, Inc. | ex99-11072017_091130.htm |
(Exact name of registrant as specified in its charter.)
(State or other jurisdiction of incorporation or organization)
(IRS Employer Identification No.)
(Address of principal executive offices)
(Registrant's Telephone number)
(Former Name or Former Address, if Changed Since Last Report)
On November 6, 2017, VistaGen Therapeutics, Inc. (the "Company") announced that the European Patent Office (EPO) granted a European Patent for AV-101, the Company's oral CNS drug candidate in Phase 2 development for major depressive disorder (MDD). The patent relates to the treatment of depression, Parkinson's disease levodopa-induced dyskinesia (PD LID) and use of multiple dosage forms to treat these CNS disorders. The patent has been validated in Belgium, Denmark, France, Germany, Ireland, Italy, Portugal, Spain, Switzerland and the United Kingdom. It will be in effect until January 2034. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1, and is incorporated herein by reference.
See Exhibit List
VistaGen Therapeutics, Inc. |
By: | /s/ Shawn K. Singh |
Name: Shawn K. Singh | |
Title: Chief Executive Officer |
Exhibit No.
|
Description
|
|
EX-99.1
|
Press release issued by VistaGen Therapeutics Inc., dated November 6, 2017.
|